Novo Nordisk has announced that its GLP-1 medications, Ozempic and Wegovy, which have been in short supply since March 2022, are now available in the U.S. and are being regularly shipped to wholesalers.

However, patients may still face challenges in filling their prescriptions at specific pharmacies.

Novo Nordisk has invested billions of dollars to enhance its manufacturing capacity to meet the increasing demand for these medications.

The demand for these GLP-1 medications has surged due to their weight-loss capabilities.

Eli Lilly, a competitor of Novo Nordisk, has also experienced supply challenges with its similar drugs, Mounjaro and Zepbound.

The availability of tirzepatide, an alternative version of the active ingredient in these drugs, is being reassessed by the FDA due to ongoing legal disputes.

The pharmaceutical industry will closely monitor Novo Nordisk's performance and the availability of Ozempic and Wegovy, as it could have significant implications for the market and the healthcare sector.